Kansè pwostat se dezyèm kansè ki pi komen nan gason atravè lemond, ak yon estimasyon 1.276 milyon nouvo ka ki te rapòte nan 2018, ki reprezante 7.1% nan tout ka kansè nan gason.
Pousantaj mòtalite pou kansè pwostat tou wo, ak yon estimasyon 37,005 lanmò atravè lemond nan 2018.
Sepandan, to mòtalite a varye anpil selon rejyon an, avèk Afrik Lwès ki gen senkyèm pi gwo risk pou mòtalite kansè pwostat nan mond lan, ak Nijerya ki gen pi gwo popilasyon ak ekonomi nan rejyon sa a.
Nan Nijerya, kansè pwostat se tou de kansè ki pi komen ak pi fatal pou gason, ak yon estimasyon 32.8 ka ak 16.3 lanmò pou chak 100,000 gason.
Sa se plis ke de fwa to lanmò nan Amerik di Nò.
Deteksyon an reta nan maladi a, resous limite pou depistaj ak deteksyon, ak diminye dokimantasyon ak rapò sou ka kontribye nan to mòtalite segondè nan Nijerya.
Ozetazini, kansè pwostat se dezyèm kòz ki pi komen pou lanmò kansè nan gason, ak apeprè 40,0000 gason ki mouri nan maladi a chak ane.
Pousantaj lanmò kansè pwostat la te tou dousman diminye depi kòmansman ane 1990 yo, men li rete yon enkyetid sante enpòtan.
An jeneral, kansè pwostat se yon maladi ki ka touye moun, patikilyèman nan rejyon ki gen aksè limite pou swen medikal ak resous pou tès depistaj.
Sepandan, deteksyon bonè ak tretman kapab amelyore rezilta yo anpil epi redwi to mòtalite yo.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Avètisman: medikal']
['Sit entènèt sa a se pou rezon edikasyonèl ak enfòmasyon sèlman e li pa bay konsèy medikal oswa sèvis pwofesyonèl.']
['Enfòmasyon yo bay la pa dwe itilize pou fè dyagnostik oswa trete yon pwoblèm sante oswa maladi, e moun k ap chèche konsèy medikal pèsonèl ta dwe konsilte yon doktè ki gen lisans.']
['Tanpri note ke rezo neural ki jenere repons pou kesyon yo, pa egzat sitou lè li rive pou kontni nimerik. pa egzanp, kantite moun ki te dyagnostike ak yon maladi espesifik.']
['Toujou chèche konsèy doktè ou oswa lòt founisè sante ki kalifye konsènan yon kondisyon medikal. Pa janm meprize konsèy medikal pwofesyonèl oswa reta nan chèche li paske nan yon bagay ou te li sou sit entènèt sa a. Si ou panse ou ka gen yon ijans medikal, rele 911 oswa ale nan sal ijans ki pi pre a imedyatman. Pa gen okenn relasyon doktè-pasyan ki kreye pa sit entènèt sa a oswa itilizasyon li yo. Ni BioMedLib ni anplwaye li yo, ni okenn kontribitè nan sit entènèt sa a, fè okenn reprezantasyon, eksprime oswa enplisit, ki gen rapò ak enfòmasyon yo bay isit la oswa pou itilize li yo.']
['Avètisman: dwa otè']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) bay rekou pou mèt copyright ki kwè ke materyèl ki parèt sou entènèt la vyole dwa yo anba lwa copyright Etazini. ']
['Si ou kwè ak tout konfyans ke nenpòt kontni oswa materyèl ki disponib an koneksyon avèk sit entènèt nou an oswa sèvis vyole copyright ou, ou (oswa ajan ou) ka voye nou yon avi pou mande pou retire kontni an oswa materyèl la, oswa aksè a li bloke.']
['Anons yo dwe voye alekri pa imel (gade seksyon "Kontak" pou adrès imel)']
['DMCA mande pou avi ou sou vyolasyon dwa otè a genyen enfòmasyon sa yo: (1) deskripsyon travay ki gen dwa otè a ki sijè vyolasyon an; (2) deskripsyon kontni ki vyole dwa otè a ak enfòmasyon ki sifi pou pèmèt nou jwenn kontni an; (3) enfòmasyon pou kontakte ou, ki gen ladan adrès ou, nimewo telefòn ou ak adrès imel ou; (4) yon deklarasyon ou fè ki di ou gen bon lafwa ke kontni an nan fason ou pote plent la pa otorize pa mèt pwopriyete dwa otè a, oswa ajan li, oswa pa operasyon nenpòt lwa; ']
['(5) yon deklarasyon ou siyen sou penalite fo temwayaj ke enfòmasyon ki nan notifikasyon an egzat e ke ou gen otorite pou fè respekte dwa otè yo ke yo reklame ke yo vyole yo;']
['e (6) yon siyati fizik oubyen elektwonik mèt copyright la oubyen yon moun ki otorize pou aji sou non mèt copyright la. ']
['Si ou pa bay tout enfòmasyon ki anwo yo, sa ka fè ke nou pa trete plent ou a byen vit.']
['Kontak']
['Tanpri voye nou yon imèl avèk nenpòt kesyon / sijesyon.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['sou']
['BioMedLib itilize òdinatè otomatik (algoritm aprantisaj machin) pou jenere pè kesyon ak repons.']
['Nou kòmanse ak 35 milyon piblikasyon biomedik de PubMed/Medline. tou, paj entènèt de RefinedWeb.']
